Creo Medical Group PLC (CREO)
Industry Medical Devices
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
12.75p
Buy
13.00p
-0.125p (-0.96%)
Creo Medical Group PLC is a medical device company focused on surgical endoscopy. It has developed an electrosurgical platform that delivers microwave and bipolar radiofrequency.
Prices updated at 01 Apr 2025, 16:03 BST
| Prices minimum 15 mins delay
|
Prices in GBX
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| - | - | - | 13,473 | 9m | 25m | 27m | 31m | |
| - | - | - | 4,951 | 4m | 12m | 13m | 15m | |
| -4m | -9m | -10m | -19m | -23m | -30m | -31m | -25m | |
| - | - | - | -140,097.81 | -249.06 | -118.86 | -112.87 | -80.52 | |
| -3m | -8m | -8m | -16m | -20m | -25m | -27m | -22m | |
| -4m | -9m | -10m | -18m | -22m | -27m | -27m | -21m | |
| Sales, General and administrative | 4m | 9m | 11m | 19m | 28m | 42m | 44m | 41m |
| Interest expenses | 2,566 | 3,319 | 7,604 | 23,397 | 173,000 | 363,000 | 300,000 | 400,000 |
| Provision for income taxes | -468,193 | -1m | -2m | -3m | -3m | -6m | -4m | -3m |
| Operating expenses | 4m | 9m | 10m | 19m | 28m | 41m | 44m | 40m |
| Income before taxes | -4m | -9m | -10m | -19m | -23m | -30m | -31m | -24m |
| Net income available to common shareholders | -3m | -8m | -8m | -16m | -20m | -25m | -27m | -22m |
| -0.039762 | -0.122425 | -0.096385 | -0.125351 | -0.125351 | -0.144764 | -0.144764 | -0.07 | |
| Net interest income | 3,222 | 2,018 | 287 | 287,891 | 5,000 | -332,000 | -200,000 | 300,000 |
| Advertising and promotion | - | - | - | - | - | - | - | - |
| Net investment income, net | - | - | - | - | - | - | - | - |
| Realised capital gains (losses), net | - | - | - | - | - | - | - | - |
| Total benefits, claims and expenses | - | - | - | - | - | - | - | - |
| Earnings per share (diluted) | -0.039762 | -0.122425 | -0.096385 | -0.125351 | -0.125351 | -0.144764 | -0.144764 | -0.07 |
| Free cash flow per share | -0.0391 | -0.1147 | -0.0934 | -0.0503 | -0.1214 | -0.1196 | -0.201 | -0.1099 |
| Book value/share | 0.0195 | 0.175 | 0.0586 | 0.26 | 0.4531 | 0.2784 | 0.3248 | 0.191 |
| Debt equity ratio | 0.006337 | 0.000099 | - | 0.00658 | 0.104162 | 0.070583 | 0.123732 | 0.086957 |
Balance sheet
Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Current assets | 4m | 16m | - | 86m | 61m | 61m | 34m | 38m |
| Current liabilities | 512,376 | 1m | - | 5m | 22m | 20m | 17m | 10m |
| Total capital | 3m | 15m | - | 83m | 68m | 77m | 54m | 64m |
| Total debt | 31,589 | 15,221 | - | 717,085 | 12m | 11m | 12m | 8m |
| Total equity | 3m | 15m | - | 83m | 63m | 73m | 49m | 60m |
| Total non current liabilities | - | - | - | - | - | - | - | - |
| Loans | - | - | - | 357,322 | 5m | 4m | 5m | 4m |
| Total assets | 4m | 16m | - | 88m | 94m | 101m | 75m | 77m |
| Total liabilities | - | - | - | - | - | - | - | - |
| Cash and cash equivalents | 3m | 14m | - | 81m | 45m | 44m | 13m | 3m |
| Common stock | 84m | 84m | - | 156m | 164m | 188m | 188m | 361m |
Cash flow
Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Cash at beginning of period | 305,244 | 823,283 | 14m | 45m | 81m | 45m | 44m | 13m |
| Cash dividends paid | - | - | - | - | - | - | - | - |
| -3m | -7m | -8m | -13m | -17m | -32m | -28m | -23m | |
| Investments (gains) losses | -138,981 | -220,377 | -825,930 | -806,513 | -21m | -8m | -6m | -18m |
| 3m | 14m | 6m | 81m | 45m | 44m | 13m | 3m | |
| Net income | - | - | - | - | - | - | - | - |
| -3m | -7m | -7m | -12m | -16m | -26m | -25m | -22m | |
| -145,780 | -225,714 | -846,099 | -1m | -576,233 | -6m | -3m | -2m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
